155 related articles for article (PubMed ID: 24320058)
1. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
Semczuk A; Skomra D; Chyzyńska M; Szewczuk W; Olcha P; Korobowicz E
Pathol Res Pract; 2008; 204(3):203-7. PubMed ID: 18207653
[TBL] [Abstract][Full Text] [Related]
4. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
6. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
7. Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.
Nishimura I; Ohishi Y; Oda Y; Kishimoto J; Yasunaga M; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Virchows Arch; 2011 Jan; 458(1):85-94. PubMed ID: 21046151
[TBL] [Abstract][Full Text] [Related]
8. COX-2 expression in uterine carcinosarcoma.
Menczer J; Schreiber L; Sukmanov O; Kravtsov V; Berger E; Golan A; Levy T
Acta Obstet Gynecol Scand; 2010; 89(1):120-5. PubMed ID: 19900134
[TBL] [Abstract][Full Text] [Related]
9. Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma.
Richmond AM; Blake EA; Torkko K; Smith EE; Spillman MA; Post MD
Int J Gynecol Cancer; 2017 Nov; 27(9):1895-1903. PubMed ID: 28704324
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma.
Wang L; Huang X; Chen Y; Jin X; Li Q; Yi TN
Eur J Surg Oncol; 2012 Jul; 38(7):568-73. PubMed ID: 22595739
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of ovarian carcinosarcomas: a single institution experience.
Zorzou MP; Markaki S; Rodolakis A; Kastritis E; Bozas G; Dimopoulos MA; Papadimitriou CA
Gynecol Oncol; 2005 Jan; 96(1):136-42. PubMed ID: 15589592
[TBL] [Abstract][Full Text] [Related]
13. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
14. Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G; Wabersich J; Ludwig K; Gardiman MP; Borgato L; Garbin F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):98-104. PubMed ID: 25468677
[TBL] [Abstract][Full Text] [Related]
15. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
Ioffe YJ; Li AJ; Walsh CS; Karlan BY; Leuchter R; Forscher C; Cass I
Gynecol Oncol; 2009 Dec; 115(3):466-71. PubMed ID: 19767065
[TBL] [Abstract][Full Text] [Related]
16. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Enomoto T; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Surg Oncol; 2018 Sep; 25(9):2756-2766. PubMed ID: 29971677
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma.
Uehara T; Onda T; Togami S; Amano T; Tanikawa M; Sawada M; Ikeda S; Kato T; Kasamatsu T
Int J Gynecol Cancer; 2012 Feb; 22(2):280-5. PubMed ID: 22228427
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.
Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():51-55. PubMed ID: 31739121
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.
Huang GS; Arend RC; Li M; Gunter MJ; Chiu LG; Horwitz SB; Goldberg GL
Am J Obstet Gynecol; 2009 Apr; 200(4):457.e1-5. PubMed ID: 19200930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
